We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging Argenx (ARGX) This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. argenex SE (ARGX - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
argenex SE is one of 1025 individual stocks in the Medical sector. Collectively, these companies sit at #2 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. argenex SE is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past three months, the Zacks Consensus Estimate for ARGX's full-year earnings has moved 87.4% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the latest available data, ARGX has gained about 42.7% so far this year. In comparison, Medical companies have returned an average of 7.2%. This shows that argenex SE is outperforming its peers so far this year.
Entera Bio Ltd. (ENTX - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 206.7%.
The consensus estimate for Entera Bio Ltd.'s current year EPS has increased 8% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, argenex SE is a member of the Medical - Biomedical and Genetics industry, which includes 504 individual companies and currently sits at #73 in the Zacks Industry Rank. Stocks in this group have lost about 1.2% so far this year, so ARGX is performing better this group in terms of year-to-date returns. Entera Bio Ltd. is also part of the same industry.
Investors with an interest in Medical stocks should continue to track argenex SE and Entera Bio Ltd. These stocks will be looking to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Are Medical Stocks Lagging Argenx (ARGX) This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. argenex SE (ARGX - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
argenex SE is one of 1025 individual stocks in the Medical sector. Collectively, these companies sit at #2 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. argenex SE is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past three months, the Zacks Consensus Estimate for ARGX's full-year earnings has moved 87.4% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the latest available data, ARGX has gained about 42.7% so far this year. In comparison, Medical companies have returned an average of 7.2%. This shows that argenex SE is outperforming its peers so far this year.
Entera Bio Ltd. (ENTX - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 206.7%.
The consensus estimate for Entera Bio Ltd.'s current year EPS has increased 8% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, argenex SE is a member of the Medical - Biomedical and Genetics industry, which includes 504 individual companies and currently sits at #73 in the Zacks Industry Rank. Stocks in this group have lost about 1.2% so far this year, so ARGX is performing better this group in terms of year-to-date returns. Entera Bio Ltd. is also part of the same industry.
Investors with an interest in Medical stocks should continue to track argenex SE and Entera Bio Ltd. These stocks will be looking to continue their solid performance.